Pablo J. Cagnoni, M.d.

Biography

Pablo is President and CEO of Tizona. Over of the course of his career as an oncologist and pharmaceutical executive, Pablo has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases. He has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blincyto® Exjade®, Folotyn® Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna® and Zykadia® among others. Most recently, he served as President of Onyx Pharmaceuticals, where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. At the time of his departure, Onyx was on track to deliver yearly revenues in excess of $1B and had more than 800 employees. Pablo joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen (Nasdaq: AMGN) subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology (NYSE: NVS), where he was responsible for all clinical development, clinical operations, clinical pharmacology, and correlative sciences activities for the oncology development pipeline. From 2007 to 2009, Pablo was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals, NASDAQ:SPPI) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas, TSE:4503). Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants.

Research Interest

Pablo is President and CEO of Tizona. Over of the course of his career as an oncologist and pharmaceutical executive, Pablo has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases. He has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blincyto® Exjade®, Folotyn® Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna® and Zykadia® among others. Most recently, he served as President of Onyx Pharmaceuticals, where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. At the time of his departure, Onyx was on track to deliver yearly revenues in excess of $1B and had more than 800 employees. Pablo joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen (Nasdaq: AMGN) subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology (NYSE: NVS), where he was responsible for all clinical development, clinical operations, clinical pharmacology, and correlative sciences activities for the oncology development pipeline. From 2007 to 2009, Pablo was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals, NASDAQ:SPPI) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas, TSE:4503). Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants.